Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
GPi vs STN deep brain stimulation for Parkinson disease
NSTAPS study group
Research output
:
Contribution to journal
›
Article
›
peer-review
196
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'GPi vs STN deep brain stimulation for Parkinson disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Subthalamic nucleus Deep Brain Stimulation (STN-DBS)
100%
Parkinson's Disease
100%
Globus Pallidus Internus
100%
Deep Brain Stimulation
54%
Subthalamic nucleus
54%
Motor Symptoms
36%
Composite Score
27%
Between-group Difference
18%
Adverse Effects
9%
Motor Behavior
9%
Behavioral Effects
9%
Reoperation
9%
Primary Outcome Measure
9%
Patients with Parkinson's Disease
9%
Advanced Parkinson's Disease
9%
After Surgery
9%
Motor Function
9%
Mood Effects
9%
Cognitive Effects
9%
Unified Parkinson's Disease Rating Scale (UPDRS)
9%
3-year Follow-up
9%
Motor Improvement
9%
Levodopa Equivalent Dose
9%
Disability Scale
9%
Motor Cognition
9%
Medicine and Dentistry
Parkinson's Disease
100%
Electrical Brain Stimulation
100%
Globus pallidus
100%
Subthalamic Nucleus
100%
Adverse Event
7%
Drug Therapy
7%
Reoperation
7%
Levodopa
7%
Cognitive Effect
7%
Equivalent Dose
7%
Unified Parkinson's Disease Rating Scale
7%
Behavioral Effect
7%
Neuroscience
Parkinson's Disease
100%
Electrical Brain Stimulation
100%
Subthalamic Nucleus
100%
Globus pallidus
100%
Behavior (Neuroscience)
15%
Behavioral Effect
7%
Adverse Effect
7%
L-DOPA
7%
Cognitive Effect
7%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Adverse Event
25%
Behavioral Effect
25%
Levodopa
25%